Introduction
Breast cancer is one of the most common non-cutaneous type of cancer in women in worldwide and a leading cause of cancer-related deaths, and is increasing year by year in almost every areas of the globe. Breast cancer is commonly classified into the following two major types: (1) non-invasive breast cancer (cancer cells are confined within the duct and lobules) and (2) invasive breast cancer (cancer cells invade through the walls of the duct or lobules and infiltrate the surrounding tissues). Various kinds of treatments are available for breast cancer, such as chemotherapy, radiotherapy and hormone therapy (Ragaz, 2009 ). Many indole derivatives are reported as potent breast cancer agents, such as aplysinopsin analogs and indole-3-carbinols. Aplysinopsins are indole-derived marine natural products. The parent aplysinopsin was isolated for the first time (Kazlauskas, et al, 1977) as the major metabolite of eight Indo-Pacific sponge species, which are representatives of the genus Thorecta. The N-1-unsubstituted aplysinopsins have generated considerable interest due to their potentially useful medicinal properties (Dobroslawa, et al, 2009) . Aplysinopsin has been reported as a potent cytotoxic agent against the Kβ-cell line and methyl-aplysinopsins against L-1210 and Kβ-cell lines has been reported as potent cytotoxic agents (Hollenbeak & Schmitz, 1977) , and the anticancer activities of aplysinopsin and methyl-aplysinopsins against both 1210-and Kβ-cells has also been reported (Kondo et al. 1994) . Indole-3-carbinol, a phytochemical derived from cruciferous vegetables such as broccoli and Brussel sprouts, exhibits potent antiproliferative effects against human breast cancer cells and has been shown to decrease metastatic spread of tumors in experimental animals (Brew, et al., 2010) . From the above observations and as part of a program for the development of small molecules as potential anticancer treatments , we initiated a drug discovery program to identify novel benzylaplysinopsin analogs as potent breast cancer agents. Combretastins are plant products from the South African tree Combretum caffrum. This compound was found to inhibit tubulin polymerization, and competitively inhibit the binding of radiolabeled colchicines to tubulin. Investigation of combretastatins revealed that combrestastatin A-4 was active against multidrug resistant (MDR) cancer cell lines (McGown, et al., 1990; Lin, et al., 1988 and Cushman, et al 1991) . Combretastatin (A-4), as well as its trans-isomer and a number of related substances, has been found to cause mitotic arrest in cells in culture at cytotoxic concentrations. trans-Tetrahydroxystilbene and a number of other related substances were also reported to be cytotoxic agents (Lin, et al 1988) . Also, many natural products possessing a trimethoxybenzene ring, e.g., colchicines, and podophyllotoxins, were found to be potent cytotoxic agents that exert their antitumor property by their antitubulin character. In view of the known antitubulin activity of combretstatin, a large number of its derivatives have been synthesized and evaluated for antitubulin activity. Some of the structural modifications carried out on these molecules are emerging as potent breast cancer agents. These observations encouraged us to also investigate combretastatin analogs as potent breast cancer agents. Both the naturally occurring stilbene derivatives i.e. resveratrol (trans-3,5,4'-trihydroxystilbene) and structurally related combretastatin analogs have been reported as cytotoxic agents. Resveratrol is one of the phytoalexins widely distributed in plants products such as grapes, berries, peanuts, and red wine. Resveratrol has recently been reported as a potential chemotherapeutic agent due to its striking inhibitory effects on cellular events associated with cancer initiation, promotion, and progression (Jang, et al., 1997) . In addition, there are several reports on the anti-cancer activity of resveratrol in animal models (Baur, et al., 2006) . Resveratrol interacts with multiple molecular targets in vitro, and exhibits cytotoxic effects against breast, skin, gastric, colon, esophageal, prostate, and pancreatic cancer cells, and leukemia cells (Baur, et al., 2006) . Based on the anticancer activity of resveratrol analogs we also focused on the synthesis several resveratrol analogs as potent breast cancer agents.
2.1 Synthesis and evaluation of in vitro anticancer activity of (Z)-5-((N-benzyl-1H-indol-3-yl) methylene) imidazolidine-2,4-diones and (Z)-5-((1-benzyl-1H-indol-3-yl) methylene)thiazolidine-2,4-diones A series of novel substituted (Z)-5-((N-benzyl-1H-indol-3-yl)methylene)imidazolidine-2,4-diones and (Z)-5-((1-benzyl-1H-indol-3-yl)methylene)thiazolidine-2,4-diones that incorporate a variety of substituents in both the indole and N-benzyl moieties, and that are considered structurally related to the natural product, aplysinopsin, were synthesized utilizing aldol condensation chemistry under both microwave irradiation and conventional heating methodologies (Scheme 1). A library of simple and substituted N-benzylindole-3-carboxaldehydes were synthesized in 85-90% yield by reacting the corresponding indole-3-carboxaldehydes with various substituted benzyl halides under phase-transfer catalytic (PTC) conditions using triethylbenzyl ammonium chloride (TEBA) and 50% w/v aqueous NaOH solution in dichloromethane (Scheme 1). Aldol condensation of the appropriate Nbenzylindole-3-carboxaldehyde with hydantoin or 2-iminothiazolidin-4-one, in the presence of CH 3 COOH and ammonium acetate and utilizing both microwave irradiation and conventional heating methods (Scheme 1), afforded a series of novel simple and substituted (Z)-5-((N-benzyl-1H-indol-3-yl)methylene)imidazolidine-2,4-diones (3a-s) and (Z)-5-((1-benzyl-1H-indol-3-yl) methylene) thiazolidine-2,4-diones (4a-i) ( Table 1) . Microwave irradiation using an open vessel in a domestic microwave oven (1100 W; Kenmore) at atmospheric pressure afforded product yields in the range of 85-93% in 30-60s. All the synthesized compounds were fully characterized by 1 H NMR, 13 C NMR. The resulting analogs were evaluated for their anti-proliferative activity against a panel of human MCF-7, MDA-MB-231/ATCC, HS-578T, BT-549, T-47D, MDA-MB-468 breast cancer cell lines (Tables 1-3) . Table 3 . IC 50 values for compounds 3n and 4c.
Synthesis and in vitro cytotoxicity evaluation of (Z)-2-amino-5-(1-benzyl-1H-indol-3-yl) methylene-1-methyl-1H-imidazol-4(5H)-ones
Another series of substituted (Z)-2-amino-5-(1-benzyl-1H-indol-3-yl)methylene-1-methyl-1H-imidazol-4(5H)-ones were synthesized (Scheme 2) utilizing similar aldol condensation chemistry. Simple and substituted N-benzylindole-3-carboxaldehydes were synthesized in 85-90% yield by reacting the corresponding indole-3-carboxaldehydes with various substituted benzyl halides under phase-transfer catalytic (PTC) conditions using triethylbenzyl ammonium chloride (TEBA) and 50% w/v aqueous NaOH solution in dichloromethane. Aldol condensation of the appropriate N-benzylindole-3-carboxaldehyde with creatinine, in the presence of CH 3 COOH and sodium acetate and utilizing both microwave irradiation and conventional heating methods (Scheme 2), afforded a series of novel simple and substituted (Z)-2-amino-5-(1-benzyl-1H-indol-3-yl)methylene-1-methyl-1H-imidazol-4(5H)-ones. Evaluation of analogs these analogs for in vitro cytotoxicity activity against MCF-7, MDA-MB-231/ATCC, HS-578T, BT-549, T-47D, MDA-MB-468 human breast cancer cell lines is shown in Table 4 (Narsimha . From this series, compounds, (Z)-2-amino-5-((1-(2-bromobenzyl)-1H-indol-3-yl)methylene)-1-methyl-1H-imidazol-4-(5H)-one (5e) and (Z)-methyl 4-((3-((2-amino-1-methyl-4-oxo-1H-imidazol-5(4H)-ylidene)methyl)-1H-indol-1-yl)methyl)benzoate (5f) showed good growth inhibition with GI 50 values ranging from 1.5µM-4µM, and LC 50 values ranging from 5.7 µM->100 µM ( Scheme 2. Synthesis of (Z)-2-amino-5-(1-benzyl-1H-indol-3-yl)methylene-1-methyl-1H-imidazol-4(5H)-one analogs: Reagents and conditions (a) appropriate benzyl halide, aqueous NaOH solution, triethylbenzyl ammonium chloride, DCM, RT; (b) Creatinine (1.1 mol. eq), NaOAc (1.2 mol. eq), AcOH, MWI, 30-60 sec; (c) Creatinine (1.1 mol. eq), NaOAc (1.2 mol. eq), AcOH, reflux, 7-10 h.
Synthesis and invitro cytotoxicity evaluation of N-alkyl-3-hydroxy-3-(2-imino-3-methyl-5-oxo-imidazolidin-4-yl)indolin-2-one A third series of N-alkyl-3-hydroxy-3-(2-imino-3-methyl-5-oxo-imidazolidin-4-yl)indolin-2-one
analogs that incorporated a variety of substituents in both the isatin phenyl and N-benzyl moieties were also synthesized. These novel analogs (8a-w) were prepared by condensation of the appropriate substituted N-alkyl isatin with creatinine, in the presence of sodium acetate and acetic acid via both microwave irradiation and conventional heating methodologies (Scheme 3) (Narsimha . Of these two methods, microwave irradiation was found to be advantageous over conventional heating, since the product yields were 83-94% for the former method, but only 70-83% for the latter method. In addition, the time course of the reaction was very fast using microwave irradiation (20-40 sec) compared to 6-8 h for conventional heating. The simple and N-alkyl substituted isatins (6a-j) were all prepared utilizing literature methods (Macpherson, et al., 2007; Jacobs, et al., 1948 and Shindikar, et al., 2006) . All the synthesized compounds were characterized by 1 H-NMR and 13 C-NMR spectrometry. The geometry of the hydroxyl position in the representative compounds 8a, 8b and 8t was established as trans to the 4′-methyne hydrogen from X-ray crystallographic data (Narsimha . From the X-ray diffraction and 1 H-NMR data, analogs 8a-8w were mixtures of RR and SS isomers. This is consistent with the mechanism of the aldol condensation reaction of 6 with 7, which proceeds via the formation of the E-enolate, as per the Zimmerman-Traxler model, which favors anti products, and is predicted to lead to the formation of equimolar RR and SS enantiomers. We also determined from the crystal structures of 8a, 8b and 8t that the 3-hydroxy group was trans to the 4′-methyne hydrogen, which may explain the inability of these analogs to undergo facile dehydration. The cytotoxicity data on these analogs is provided in Table 5 (Narsimha . Two analogs, 3-hydroxy-3-(2-imino-3-methyl-5-oxoimidazolidin-4-yl)-1-(4-methoxy benzyl)indolin-2-one (8n) and 5-chloro-3-hydroxy-3-(2-imino-3-methyl-5-oxoimidazolidin-4-yl)-1-(4-methoxybenzyl)indolin-2-one (8o), showed growth inhibition with GI 50 values ranging from 2µM-60µM. Substitution of a methoxy group at the 4 th position of N-benzyl group (8n) increases the activity over the breast cancer cells. Further the substitution of chloro group at 5 th position of N-benzyl p-methoxy isatin (8n) increased the activity. 
Synthesis and in vitro cytotoxicity evaluation of benzo[b]thiophene phenyl acrylontriles as novel combretastatin analogs

Synthesis and in vitro cytotoxicity evaluation of resveratrol analogs
A series of novel resveratrol analogs were synthesized (Scheme 5) and evaluated for their anti-proliferative activity against MCF-7 and MDA-231 breast cancer cells ( Table 7) . The initial step in the synthesis of resveratrol analogs 16a-i is the synthesis of the common intermediate trans -2-formyl-3,4′,5-trimethoxystilbene (15) , which was prepared via formylation of (E)-1,3-dimethoxy-5-(4-methoxystyryl)benzene (14) with a slight excess of phosphorous oxychloride (POCl 3 ) in dimethyl formamide (DMF) at 0 o C in 69% yield (Xian, et al, 2007) . The novel resveratrol analogs 16a-i were then prepared by aldol condensation of resveratrol-2-carboxaldehyde with the appropriate active methylene compound, utilizing a variety of reaction conditions, i.e., ammonium acetate in acetic acid under microwave irradiation (MWI), by refluxing the reactants in ethanol, or by stirring the reaction at ambient temperature in methanol. The synthetic routes to the resveratrol analogs 16a-i are illustrated in Scheme 5. Compounds 16a-i were fully characterized by 1 H-NMR and 13 C-NMR spectrometry. The geometry of the double bond was established as Z, based on NMR spectrometric data. The X-ray crystallographic data of the representative compound 16e confirmed the Z-geometry in this analog . The most potent compound, (Z)-5-(2,4-dimethoxy-6-(4-methoxystyryl)benzylidene)-2-imino-1-methylimidazolidin-4-one (16e), had IC 50 values of 0.99µM against MDA-231 cancer cell lines. Compound (Z)-6-(2,4-dimethoxy-6-(4-methoxystyryl)benzylidene)-dihydropyrimidine-2,4,5(3H)-trione (16c) had an IC 50 value of 1.28µM against the MCF-7 cell line. The resveratrol analog, (E)-5-(2,4-dimethoxy-6-(4-methoxystyryl)benzylidene)-2-iminothiazolidin-4-one (16i) was also evaluated for its in vitro cytotoxicity against a panel of human MCF-7, MDA-MB-231/ATCC, HS-578T, BT-549, T-47D, breast cancer cell lines (Table 8) . This compound showed growth inhibition (GI 50 values ranging from 1.4µM-3.9µM) and cytotoxicity (LC 50 values ranging from 7.1µM-65.7µM) amongst four out of five of the breast cancer cell lines utilized. Table 8 . Growth inhibition (GI 50 / µM) a and cytotoxicity (LC 50 / µM) b data of (Z)-2-amino-5-(2,4-dimethoxy-6-(4-methoxystyryl) benzylidene)thiazol-4(5H)-one (16i).
Breast Cancer
Conclusion
In conclusion, novel N-benzyl aplysinopsin, combretastatin and resveratrol analogs have been synthesized and evaluated for their anticancer activity against a number of breast cell lines. In the N-benzyl aplysinopsin series, the analog (Z)-methyl-1-(4-cyanobenzyl)-3-((2,5-dioxoimidazolidin-4-ylidene)methyl)-1H-indole-6-carboxylate (3n) emerged as promising lead compound for further structural optimization studies. The novel combretastatin analogs, (Z)-3-(benzo [b] thiophen-3-yl)-2-(3,4-dimethoxyphenyl)acrylonitrile (11b), and (Z)-3-(benzo [b] thiophen-3-yl)-2-(3,4,5-trimethoxy phenyl)acrylonitrile (11c) were shown to be potent cytotoxic agents against breast cancer cell lines in culture and worthy of further evaluation in animal models of breast cancer. From the library of novel resveratrol analogs, the creatinine analog, (Z)-5-(2, 4-dimethoxy-6-(4-methoxystyryl)benzylidene)-2-imino-1-methylimidazolidin-4-one (16e) was considered as a lead analog for subsequent structural optimization as a potential agent for the treatment of breast cancer.
